Taiwan FDA registration 7a3bde0a72fa6c811ace2fbdc08fc916
"Haifeng Biomedicine" Dabigatran correction solution
TW: “海奉生物醫學” Dabigatran 校正液
Taiwan·Risk Class 2·HYPHEN BioMed·Registered Nov 09, 2020 – Nov 09, 2025ExpiredRegistration details
- Analysis ID
- 7a3bde0a72fa6c811ace2fbdc08fc916
- Customs Code
- DHA05603415507
Company information
- Manufacturer
- HYPHEN BioMed
- Manufacturer Country
- France
- Authorized Representative
- SYSMEX TAIWAN CO., LTD.
Product details
- Intended Use
- This product is lyophilized human plasma doped with different concentrations of Dabigatran for correction of Dabigatran measurements.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1150 Calibrated Products
- Import Information
- QMS/QSD;; 輸入
Dates and status
- Registration Date
- Nov 09, 2020
- Expiry Date
- Nov 09, 2025
About this record
Access comprehensive regulatory information for "Haifeng Biomedicine" Dabigatran correction solution in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 7a3bde0a72fa6c811ace2fbdc08fc916 and manufactured by HYPHEN BioMed. The authorized representative in Taiwan is SYSMEX TAIWAN CO., LTD..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices